Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 4/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.39 |
| ▸ | SRC | P12931 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | PIM1 | P11309 | 2/20 | 0.38 |
| ▸ | PRKACA | P17612 | 2/20 | 0.38 |
| ▸ | GSK3B | P49841 | 2/20 | 0.38 |
| ▸ | AURKA | O14965 | 1/20 | 0.38 |
| ▸ | CDK1 | P06493 | 1/20 | 0.38 |
| ▸ | LYN | P07948 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL564993 | 0.88 | SMN1; SMN2 (0.46) | SMN1; SMN2ALDH1A1HSD17B10HPGDKMT2A | |
| SCHEMBL11775647 | 0.68 | SMN1; SMN2 (0.47) | SMN1; SMN2HSD17B10HPGDKMT2AKDM4E | |
| SCHEMBL5963314 | 0.68 | HPGD (0.68) | DYRK1ASMN1; SMN2ALDH1A1HSD17B10HPGD | |
| SCHEMBL22086169 | 0.67 | SRC (0.85) | DYRK1ASMN1; SMN2KMT2AMAPTSRC | |
| SCHEMBL14701115 | 0.67 | DYRK1A (0.45) | DYRK1ASMN1; SMN2NOTUMALDH1A1HSD17B10 | |
| SCHEMBL22032007 | 0.66 | SRC (0.55) | DYRK1ASMN1; SMN2ALDH1A1HSD17B10HPGD | |
| SCHEMBL11000015 | 0.66 | KDM4E (0.45) | SMN1; SMN2NOTUMALDH1A1HSD17B10HPGD | |
| SCHEMBL3263136 | 0.66 | MAPT (0.55) | SMN1; SMN2ALDH1A1KMT2AKDM4EL3MBTL1 | |
| SCHEMBL11827884 | 0.65 | BRD4 (0.47) | SMN1; SMN2ALDH1A1HSD17B10KDM4EMAPT | |
| SCHEMBL7656228 | 0.65 | ALDH1A1 (0.49) | SMN1; SMN2NOTUMALDH1A1HSD17B10HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1856100-B1 | CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2010-05-05 | — | — | EP | disclosed |
| US-7632832-B2 | CGRP receptor antagonists | MERCK & CO., INC. (US) | 2009-12-15 | — | — | US | disclosed |
| EP-1856100-A4 | CGRP RECEPTOR ANTAGONISTS | MERCK & CO INC (US) | 2009-04-15 | — | — | EP | disclosed |
| WO-2008070014-A2 | BIARYL KETONE-SUBSTITUTED PIPERIDINES | NEUROGEN CORPORATION (US) | 2008-06-12 | — | — | WO | disclosed |
| US-20080125413-A1 | Cgrp Receptor Antagonists | MERCK SHARP & DOHME LLC | 2008-05-29 | — | — | US | disclosed |
| WO-2008060568-A2 | AMIDE-SUBSTITUTED ARYL PIPERIDINES | NEUROGEN CORPORATION (US) | 2008-05-22 | — | — | WO | disclosed |
| EP-1856100-A2 | CGRP RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 2007-11-21 | — | — | EP | disclosed |
| WO-2006078554-A2 | CGRP RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2006-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080125413-A1 | Cgrp Receptor Antagonists | CALCRL, NPY1R, CCKBR | DYRK1A 3695/4885SMN1; SMN2 4494/4885NOTUM 3851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.